TY - JOUR AU - Jójárt, Boldizsár AU - Resál, Tamás AU - Kata, Diána AU - Molnár, Tünde AU - Bacsur, Péter AU - Szabó, Viktória AU - Varga, Árpád AU - Szántó, Kata Judit AU - Pallagi, Petra AU - Földesi, Imre AU - Molnár, Tamás AU - Maléth, József AU - Farkas, Klaudia TI - P421 The faecal biomarker LDN-051 is a novel tool for monitoring disease activity and therapeutic response in Inflammatory Bowel Diseases JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - Supplement_1 SP - i869 EP - i869 PG - 1 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad212.0551 UR - https://m2.mtmt.hu/api/publication/34538603 ID - 34538603 LA - English DB - MTMT ER - TY - JOUR AU - Jójárt, Boldizsár AU - Csákány-Papp, Noémi AU - Laub, H AU - Vasas, Béla AU - Barta, B AU - Szabó, Viktória AU - Bagyánszki, Mária AU - Mándity, I AU - Heltovics, G AU - Pallagi, Petra AU - Maléth, József TI - P072 LDN-071, a novel first-in-class amino acid-based PAI-1 inhibitor, significantly reduces the severity of experimental colitis in mice JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - Supplement_1 SP - i342 EP - i342 PG - 1 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad212.0202 UR - https://m2.mtmt.hu/api/publication/34538600 ID - 34538600 LA - English DB - MTMT ER - TY - JOUR AU - Jójárt, Boldizsár AU - Resál, Tamás AU - Kata, Diána AU - Molnár, Tünde AU - Bacsur, Péter AU - Szabó, Viktória AU - Varga, Árpád AU - Szántó, Kata Judit AU - Pallagi, Petra AU - Földesi, Imre AU - Molnár, Tamás AU - Maléth, József AU - Farkas, Klaudia TI - Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - 3 SP - 392 EP - 405 PG - 14 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad160 UR - https://m2.mtmt.hu/api/publication/34167015 ID - 34167015 N1 - Ladon Therapeutics Ltd, Szeged, Hungary Department of Medicine, University of Szeged, Szeged, Hungary ELKH-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Szeged, Hungary HCEMM-USZ Molecular Gastroenterology Research Group, University of Szeged, Szeged, Hungary Faculty of Medicine, Institute of Laboratory Medicine, University of Szeged, Szeged, Hungary Export Date: 8 April 2024 Correspondence Address: Maléth, J.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary; email: maleth.jozsef@med.uszeged.hu Correspondence Address: Farkas, K.; HAS-USZ Momentum Epithelial Cell Signalling and Secretion Research Group, Hungary Chemicals/CAS: adalimumab, 331731-18-1, 1446410-95-2; azathioprine, 446-86-6, 55774-33-9; budesonide, 51333-22-3, 51372-29-3; cyclosporine, 59865-13-3, 63798-73-2, 79217-60-0; infliximab, 170277-31-3; mesalazine, 89-57-6; plasminogen activator inhibitor 1, 140208-23-7; tofacitinib, 477600-75-2, 540737-29-9; ustekinumab, 815610-63-0, 949907-93-1; vedolizumab, 943609-66-3; Biomarkers; Plasminogen Activator Inhibitor 1 Tradenames: 201170, Greiner; ab269373, Abcam; ChemiDoc MP, Biorad; GraphPad 9.5.0, Graphpad; iScript cDNA Synthesis Kit, Biorad; MedCalc Software 20.211, MedCalc; Multiskan FC, Thermo; NucleoSpin RNA Plus Kit, Macherey Manufacturers: Abcam; Biorad; Carl Zeiss; Graphpad; Greiner; Macherey; MedCalc; Thermo AB - Crohn's disease and ulcerative colitis require lifelong treatment and patient monitoring. Current biomarkers have several limitations, therefore, there is an unmet need to identify novel biomarkers in inflammatory bowel disease (IBD). Previously, the role of plasminogen activator inhibitor 1 (PAI-1) was established in the pathogenesis of IBD and suggested as a potential biomarker. Therefore, we aimed to comprehensively analyze the selectivity of PAI-1 in IBD, its correlation with the disease activity, and its potential to predict therapeutic response.Blood, colon biopsy, organoid cultures (OC), and faecal samples were used from active and inactive IBD patients and control subjects. Serpin E1 gene expressions and PAI-1 protein levels and localization in serum, biopsy, and fecal samples were evaluated by qRT-PCR, ELISA, and immunostaining, respectively.The study population comprised 132 IBD patients (56 CD and 76 UC) and 40 non-IBD patients. We demonstrated that the serum, mucosal, and faecal PAI-1 concentration is elevated in IBD patients, showing clinical and endoscopic activity. In responders (decrease of eMayo≥3 in UC; or SES-CD>50% in CD), the initial PAI-1 level decreased significantly upon successful therapy. OCs derived from active IBD patients produced higher concentrations of PAI-1 than the controls, suggesting that epithelial cells could be a source of PAI-1. Moreover, faecal PAI-1 selectively increases in active IBD but not other organic gastrointestinal diseases.The serum, mucosal, and faecal PAI-1 concentration correlates with the disease activity and therapeutic response in IBD, suggesting that PAI-1 could be utilized as a novel non-invasive, disease-specific faecal biomarker in the patient follow-up. LA - English DB - MTMT ER - TY - GEN AU - Szabó, Viktória AU - Csákány-Papp, Noémi AU - Görög, Marietta AU - Madácsy, Tamara AU - Varga, Árpád AU - Kiss, Aletta Kata AU - Tél, Bálint AU - Jójárt, Boldizsár AU - Crul, Tim AU - Dudás, Krisztina Márta AU - Bagyánszki, Mária AU - Bódi, Nikolett AU - Ayaydin, Ferhan AU - Jee, Shyam AU - Tiszlavicz, László AU - Stauderman, Kenneth AU - Hebbar, Sudarshan AU - Pallagi, Petra AU - Maléth, József TI - Orai1 calcium channel inhibition prevents progression of chronic pancreatitis PY - 2023 UR - https://m2.mtmt.hu/api/publication/34687647 ID - 34687647 LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Viktória AU - Csákány-Papp, Noémi AU - Görög, Marietta AU - Madácsy, Tamara AU - Varga, Árpád AU - Kiss, AK AU - Tél, Bálint AU - Jójárt, Boldizsár AU - Crul, Tim AU - Dudás, Krisztina Márta AU - Bagyánszki, M AU - Bódi, N AU - Ayaydin, F AU - Jee, S AU - Tiszlavicz, L AU - Stauderman, K AU - Hebbar, S AU - Pallagi, Petra AU - Maléth, József TI - ORAI1 CALCIUM CHANNEL INHIBITION PREVENTS PROGRESSION OF RECURRENT ACUTE AND CHRONIC PANCREATITIS JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - Suppl 8 SP - 66 EP - 66 PG - 1 SN - 2050-6406 UR - https://m2.mtmt.hu/api/publication/34687430 ID - 34687430 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Tamás AU - Szabó, Viktória AU - Jójárt, Boldizsár AU - Csákány-Papp, Noémi AU - Pallagi, Petra AU - Maléth, József TI - PLASMINOGEN ACTIVATOR INHIBITOR 1 A POTENTIAL NEW THERAPEUTIC TARGET IN THE TREATMENT OF CHRONIC PANCREATITIS JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - Suppl 8 SP - 463 EP - 463 PG - 1 SN - 2050-6406 UR - https://m2.mtmt.hu/api/publication/34687367 ID - 34687367 LA - English DB - MTMT ER - TY - GEN AU - Szabó, Viktória AU - Csákány-Papp, Noémi AU - Görög, Marietta AU - Madácsy, Tamara AU - Varga, Árpád AU - Kiss, Aletta Kata AU - Tél, Bálint AU - Jójárt, Boldizsár AU - Crul, Tim AU - Dudás, Krisztina Márta AU - Bagyánszki, Mária AU - Bódi, Nikolett AU - Ayaydin, Ferhan AU - Shyam, Jee AU - Tiszlavicz, László AU - Stauderman, Kenneth AU - Hebbar, Sudarshan AU - Pallagi, Petra AU - Maléth, József TI - The inhibition of Orai1 calcium channel reduces the progression of chronic pancreatitis PY - 2023 SP - 1 UR - https://m2.mtmt.hu/api/publication/34672053 ID - 34672053 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Tünde AU - Szabó, Viktória AU - Jójárt, Boldizsár AU - Csákány-Papp, Noémi AU - Pallagi, Petra AU - Maléth, József TI - Determining the role of Serpin E1/PAI-1 in the development and progression of chronic pancreatitis JF - PANCREATOLOGY J2 - PANCREATOLOGY VL - 23 PY - 2023 SP - e65 SN - 1424-3903 DO - 10.1016/j.pan.2023.06.568 UR - https://m2.mtmt.hu/api/publication/34633221 ID - 34633221 LA - English DB - MTMT ER - TY - JOUR AU - Jójárt, Boldizsár AU - Resál, Tamás AU - Kata, Diána AU - Molnár, Tünde AU - Bacsur, Péter AU - Szabó, Viktória AU - Varga, Árpád AU - Szántó, Kata Judit AU - Földesi, Imre AU - Molnár, Tamás AU - Maléth, József AU - Farkas, Klaudia TI - LDN-051 a novel fecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases – results of a phase 2 clinical trial JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - S8 SP - 291 EP - 292 PG - 2 SN - 2050-6406 UR - https://m2.mtmt.hu/api/publication/34593890 ID - 34593890 LA - English DB - MTMT ER - TY - JOUR AU - Jójárt, Boldizsár AU - Csákány-Papp, Noémi AU - H., Laub AU - Vasas, Béla AU - Barta, Bence Pál AU - Szabó, Viktória AU - Bagyánszki, Mária AU - I., Mándity AU - G., Heltovics AU - Pallagi, Petra AU - Maléth, József TI - LDN-071, a novel first-in-class peptide-based plasminogen activator inhibitor 1, significantly reduces the severity of experimental colitis in mic JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - S8 SP - 209 EP - 2010 PG - 1802 SN - 2050-6406 UR - https://m2.mtmt.hu/api/publication/34593826 ID - 34593826 LA - English DB - MTMT ER -